Details

Autor(en) / Beteiligte

• Zhang, Yuan
• Chen, Lei
• Hu, Guo-Qing
• Zhang, Ning
• Zhu, Xiao-Dong
• Yang, Kun-Yu
• Jin, Feng
• Shi, Mei
• Chen, Yu-Pei
• Hu, Wei-Han
• Cheng, Zhi-Bin
• Wang, Si-Yang
• Tian, Ye
• Wang, Xi-Cheng
• Sun, Yan
• Li, Jin-Gao
• Li, Wen-Fei
• Li, Yu-Hong
• Tang, Ling-Long
• Mao, Yan-Ping
• Zhou, Guan-Qun
• Sun, Rui
• Liu, Xu
• Guo, Rui
• Long, Guo-Xian
• Liang, Shao-Qiang
• Li, Ling
• Huang, Jing
• Long, Jin-Hua
• Zang, Jian
• Liu, Qiao-Dan
• Zou, Li
• Su, Qiong-Fei
• Zheng, Bao-Min
• Xiao, Yun
• Guo, Ying
• Han, Fei
• Mo, Hao-Yuan
• Lv, Jia-Wei
• Du, Xiao-Jing
• Xu, Cheng
• Liu, Na
• Li, Ying-Qin
• Chua, Melvin L. K
• Xie, Fang-Yun
• Sun, Ying
• Ma, Jun

Titel

Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma

Ist Teil von

• The New England journal of medicine, 2019-09, Vol.381 (12), p.1124-1135

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2019

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• Adding three cycles of induction chemotherapy with gemcitabine and cisplatin to concurrent chemoradiotherapy improved 3-year recurrence-free survival (85.3%, vs. 76.5% with concurrent chemoradiotherapy alone) and overall survival (94.6% vs. 90.3%). Patients receiving induction chemotherapy were more likely to have grade 3 or 4 myelosuppression, nausea, and vomiting.